CSPC Pharmaceutical Welcomes New R&D President

CSPC Pharmaceutical Group (HK:1093) has released an update.

CSPC Pharmaceutical Group Limited has enthusiastically announced the appointment of Dr. Liu Yongjun as the new Executive President and the President of Global Research and Development. Dr. Liu is a distinguished scientist with over three decades of experience in the biopharmaceutical field, having held significant R&D roles at major companies like Innovent Biologics, Sanofi, and AstraZeneca. His extensive research work, which has notably impacted drug development in immunology and oncology, is highly regarded with over 260 published papers.

For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.